Skip to main content
CVKD
NASDAQ Life Sciences

Cadrenal Therapeutics Receives Clear FDA Guidance for Pivotal Phase 3 Trial of CAD-1005 in HIT

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$7.09
Mkt Cap
$18.993M
52W Low
$4.21
52W High
$16.5
52W Position info
68% above low
Off High info
57% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

CVKD sits 68% above its 52-week low of $4.21.

Summary

Cadrenal Therapeutics announced receipt of official FDA End-of-Phase 2 meeting minutes, providing clear guidance for advancing its lead drug candidate, CAD-1005, directly into a pivotal Phase 3 trial for heparin-induced thrombocytopenia (HIT).


Key Events · Product Development and Regulatory · CVKD

  • FDA Guidance for Pivotal Phase 3 Trial

    Cadrenal Therapeutics received official FDA End-of-Phase 2 meeting minutes, providing clear guidance on the protocol design, study population, dosing, and primary endpoint for the pivotal Phase 3 registration trial of CAD-1005 in heparin-induced thrombocytopenia (HIT).

  • Direct Advancement to Phase 3

    The company plans to advance directly to a randomized, blinded, placebo-controlled Phase 3 study evaluating CAD-1005 in approximately 120 patients worldwide, with a projected NDA submission in 2029. This follows positive Phase 2 data showing a significant reduction in thrombotic events.

  • Q1 Financials and Recent Financing

    Cadrenal reported a net loss of $2.5 million for Q1 2026 and held $2.3 million in cash and cash equivalents as of March 31, 2026. Subsequent to quarter-end, the company completed a $2.5 million financing on April 1, 2026, to support near-term development activities.


Analysis · CVKD · Life Sciences

This 8-K provides crucial clarity on the development path for Cadrenal's lead asset, CAD-1005, following the End-of-Phase 2 meeting with the FDA. Receiving official minutes and detailed guidance for a pivotal Phase 3 trial significantly de-risks the program and outlines a clear path towards a projected NDA submission in 2029. This positive development for their lead drug candidate, which targets a life-threatening condition, is a strong signal for the company's long-term prospects. While the company's financial position remains challenging, as highlighted in the concurrently filed 10-Q, the $2.5 million financing provides some near-term liquidity. Investors should monitor the initiation and progress of the Phase 3 trial and future financing activities.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CVKD was trading at $7.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19M. The 52-week trading range was $4.21 to $16.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CVKD - Latest Insights

CVKD
Nov 16, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.40
Real-time Price: $1.61 info
Change: +$0.210 (+15%) info
Market Cap: $7.008M info
CVKD
Oct 07, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.10
Real-time Price: $1.61 info
Change: +$0.510 (+46%) info
Market Cap: $7.008M info
CVKD
Aug 31, 2026, 8:29 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $1.61 info
Change: +$0.110 (+7%) info
Market Cap: $7.008M info
CVKD
Aug 31, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.63
Real-time Price: $1.61 info
Change: -$0.020 (-1%) info
Market Cap: $7.008M info
CVKD
Aug 13, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.86
Real-time Price: $1.61 info
Change: -$0.250 (-13%) info
Market Cap: $7.008M info